BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?

Key Takeaways BAYRY stock has surged 62.9% in 2025, far outpacing its industry, sector, and the S&P 500 index. FDA approvals for Nubeqa and Kerendia support pharma growth as Xarelto sales decline. Cost cuts, new launches and pipeline advances position BAYRY for continued recovery. The going has been good for the German pharmaceutical giant Bayer (BAYRY) this year. Shares have surged 62.9% year to date compared with the industry’s gain of 1.9%. The stock has also outperformed the sector and the S&P 500 ind ...